vs
ICU MEDICAL INC（ICUI）与Tyler Technologies（TYL）财务数据对比。点击上方公司名可切换其他公司
Tyler Technologies的季度营收约是ICU MEDICAL INC的1.1倍（$613.5M vs $540.7M），Tyler Technologies净利率更高（13.2% vs -2.9%，领先16.1%），Tyler Technologies同比增速更快（8.6% vs -14.1%），ICU MEDICAL INC自由现金流更多（$36.0M vs $2.0M），过去两年Tyler Technologies的营收复合增速更高（6.5% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
Tyler Technologies, Inc.是总部位于美国得克萨斯州普莱诺的科技企业，主营面向美国公共部门提供自研专有软件，目前在全美17个州设有办事处，另在加拿大安大略省多伦多市设有一处办公网点。
ICUI vs TYL — 直观对比
营收规模更大
TYL
是对方的1.1倍
$540.7M
营收增速更快
TYL
高出22.7%
-14.1%
净利率更高
TYL
高出16.1%
-2.9%
自由现金流更多
ICUI
多$33.9M
$2.0M
两年增速更快
TYL
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $613.5M |
| 净利润 | $-15.7M | $81.2M |
| 毛利率 | 37.5% | 48.3% |
| 营业利润率 | 1.0% | 16.3% |
| 净利率 | -2.9% | 13.2% |
| 营收同比 | -14.1% | 8.6% |
| 净利润同比 | 34.0% | — |
| 每股收益（稀释后） | $-0.63 | $1.88 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUITYL
| Q1 26 | — | $613.5M | ||
| Q4 25 | $540.7M | $575.2M | ||
| Q3 25 | $537.0M | $595.9M | ||
| Q2 25 | $548.9M | $596.1M | ||
| Q1 25 | $604.7M | $565.2M | ||
| Q4 24 | $629.8M | $541.1M | ||
| Q3 24 | $589.1M | $543.3M | ||
| Q2 24 | $596.5M | $541.0M |
净利润ICUITYL
| Q1 26 | — | $81.2M | ||
| Q4 25 | $-15.7M | $65.5M | ||
| Q3 25 | $-3.4M | $84.4M | ||
| Q2 25 | $35.3M | $84.6M | ||
| Q1 25 | $-15.5M | $81.1M | ||
| Q4 24 | $-23.8M | $65.2M | ||
| Q3 24 | $-33.0M | $75.9M | ||
| Q2 24 | $-21.4M | $67.7M |
毛利率ICUITYL
| Q1 26 | — | 48.3% | ||
| Q4 25 | 37.5% | 45.5% | ||
| Q3 25 | 37.4% | 47.2% | ||
| Q2 25 | 37.9% | 45.8% | ||
| Q1 25 | 34.7% | 47.3% | ||
| Q4 24 | 36.1% | 43.8% | ||
| Q3 24 | 34.8% | 43.7% | ||
| Q2 24 | 34.8% | 44.0% |
营业利润率ICUITYL
| Q1 26 | — | 16.3% | ||
| Q4 25 | 1.0% | 13.0% | ||
| Q3 25 | 2.6% | 16.4% | ||
| Q2 25 | 1.9% | 16.0% | ||
| Q1 25 | 2.1% | 15.8% | ||
| Q4 24 | 6.0% | 13.2% | ||
| Q3 24 | 1.4% | 15.2% | ||
| Q2 24 | 1.3% | 14.4% |
净利率ICUITYL
| Q1 26 | — | 13.2% | ||
| Q4 25 | -2.9% | 11.4% | ||
| Q3 25 | -0.6% | 14.2% | ||
| Q2 25 | 6.4% | 14.2% | ||
| Q1 25 | -2.6% | 14.3% | ||
| Q4 24 | -3.8% | 12.1% | ||
| Q3 24 | -5.6% | 14.0% | ||
| Q2 24 | -3.6% | 12.5% |
每股收益（稀释后）ICUITYL
| Q1 26 | — | $1.88 | ||
| Q4 25 | $-0.63 | $1.50 | ||
| Q3 25 | $-0.14 | $1.93 | ||
| Q2 25 | $1.43 | $1.93 | ||
| Q1 25 | $-0.63 | $1.84 | ||
| Q4 24 | $-0.97 | $1.48 | ||
| Q3 24 | $-1.35 | $1.74 | ||
| Q2 24 | $-0.88 | $1.57 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $346.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $3.6B |
| 总资产 | $4.1B | $4.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ICUITYL
| Q1 26 | — | $346.4M | ||
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $950.8M | ||
| Q2 25 | — | $892.3M | ||
| Q1 25 | — | $807.4M | ||
| Q4 24 | $308.6M | $768.0M | ||
| Q3 24 | $312.5M | $544.3M | ||
| Q2 24 | $302.6M | $258.0M |
总债务ICUITYL
| Q1 26 | — | — | ||
| Q4 25 | — | $599.7M | ||
| Q3 25 | — | $599.2M | ||
| Q2 25 | — | $598.8M | ||
| Q1 25 | — | $598.4M | ||
| Q4 24 | — | $597.9M | ||
| Q3 24 | — | $597.5M | ||
| Q2 24 | — | $597.1M |
股东权益ICUITYL
| Q1 26 | — | $3.6B | ||
| Q4 25 | $2.1B | $3.7B | ||
| Q3 25 | $2.1B | $3.6B | ||
| Q2 25 | $2.1B | $3.6B | ||
| Q1 25 | $2.0B | $3.5B | ||
| Q4 24 | $2.0B | $3.4B | ||
| Q3 24 | $2.0B | $3.3B | ||
| Q2 24 | $2.0B | $3.1B |
总资产ICUITYL
| Q1 26 | — | $4.8B | ||
| Q4 25 | $4.1B | $5.6B | ||
| Q3 25 | $4.1B | $5.5B | ||
| Q2 25 | $4.1B | $5.4B | ||
| Q1 25 | $4.2B | $5.2B | ||
| Q4 24 | $4.2B | $5.2B | ||
| Q3 24 | $4.3B | $5.0B | ||
| Q2 24 | $4.3B | $4.8B |
负债/权益比ICUITYL
| Q1 26 | — | — | ||
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | 0.17× | ||
| Q2 25 | — | 0.16× | ||
| Q1 25 | — | 0.17× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.18× | ||
| Q2 24 | — | 0.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $107.3M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $2.0M |
| 自由现金流率自由现金流/营收 | 6.6% | 0.3% |
| 资本支出强度资本支出/营收 | 4.6% | — |
| 现金转化率经营现金流/净利润 | — | 1.32× |
| 过去12个月自由现金流最近4个季度 | $91.8M | $585.7M |
8季度趋势，按日历期对齐
经营现金流ICUITYL
| Q1 26 | — | $107.3M | ||
| Q4 25 | $60.6M | $243.9M | ||
| Q3 25 | $56.7M | $255.2M | ||
| Q2 25 | $11.2M | $98.3M | ||
| Q1 25 | $51.3M | $56.2M | ||
| Q4 24 | $40.2M | $224.8M | ||
| Q3 24 | $36.1M | $263.7M | ||
| Q2 24 | $82.0M | $64.3M |
自由现金流ICUITYL
| Q1 26 | — | $2.0M | ||
| Q4 25 | $36.0M | $239.6M | ||
| Q3 25 | $27.6M | $251.3M | ||
| Q2 25 | $-8.5M | $92.8M | ||
| Q1 25 | $36.7M | $53.8M | ||
| Q4 24 | $16.1M | $221.0M | ||
| Q3 24 | $16.2M | $260.8M | ||
| Q2 24 | $62.5M | $57.7M |
自由现金流率ICUITYL
| Q1 26 | — | 0.3% | ||
| Q4 25 | 6.6% | 41.7% | ||
| Q3 25 | 5.1% | 42.2% | ||
| Q2 25 | -1.5% | 15.6% | ||
| Q1 25 | 6.1% | 9.5% | ||
| Q4 24 | 2.6% | 40.8% | ||
| Q3 24 | 2.7% | 48.0% | ||
| Q2 24 | 10.5% | 10.7% |
资本支出强度ICUITYL
| Q1 26 | — | — | ||
| Q4 25 | 4.6% | 0.8% | ||
| Q3 25 | 5.4% | 0.7% | ||
| Q2 25 | 3.6% | 0.9% | ||
| Q1 25 | 2.4% | 0.4% | ||
| Q4 24 | 3.8% | 0.7% | ||
| Q3 24 | 3.4% | 0.5% | ||
| Q2 24 | 3.3% | 1.2% |
现金转化率ICUITYL
| Q1 26 | — | 1.32× | ||
| Q4 25 | — | 3.72× | ||
| Q3 25 | — | 3.02× | ||
| Q2 25 | 0.32× | 1.16× | ||
| Q1 25 | — | 0.69× | ||
| Q4 24 | — | 3.45× | ||
| Q3 24 | — | 3.47× | ||
| Q2 24 | — | 0.95× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
TYL
| Subscriptions | $429.7M | 70% |
| Maintenance | $108.9M | 18% |
| Other | $74.9M | 12% |
